Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
批准号:
10322105
负责人:
KATHARINE C HSU
金额:
$60.84万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-05 至 2024-12-31
关键词:
Acute Myelocytic LeukemiaAffectAlgorithmsAllelesAllogenicAllograftingAntitumor ResponseBehaviorBindingBiological ModelsBone Marrow TransplantationCancer EtiologyCause of DeathCell Surface ReceptorsCellsClinicalClinical ResearchDataData ScientistDonor SelectionEducationFailureGene CombinationsGeneticGenetic PolymorphismGenotypeHLA-B AntigensImmuneImmune systemImmunogeneticsImmunologistIn VitroIncidenceIndividualInfluentialsLigandsMachine LearningMalignant NeoplasmsMediatingModelingNK cell receptor NKB1Natural Killer CellsOutcomePatientsPeptide Leader SequencesPeptidesPhenotypePhysiciansPlayPopulationPositioning AttributeProcessReceptor GeneRecurrent diseaseRelapseReproducibilityResearchRetrospective StudiesRiskRoleScientistShapesStatistical ModelsT cell responseT-LymphocyteTimeTissuesTrainingTransplant RecipientsTransplantationUnited StatesValidationVariantWorkadaptive immune responsebasecancer cellcohortcurative treatmentsdimorphismdisorder riskgraft vs host diseasegraft vs leukemia effecthematopoietic cell transplantationimmune functionin vivoleukemialeukemia relapsemachine learning modelmortalitynovel strategiespeptide Bpersonalized medicinepreventreceptorrelapse predictionresponse
中文摘要
摘要
异基因造血细胞移植(HCT)是大多数形式的急性骨髓性白血病的唯一治愈性治疗。
骨髓性白血病(AML),但其50%的失败率仍然不可接受的高,与主要
疾病复发和移植物抗宿主病导致的死亡原因。成功后,HCT可防止
由T细胞和自然杀伤(NK)细胞共同介导的移植物抗白血病效应引起的白血病复发
免疫功能。选择同种异体移植物将提供较高NK抗白血病应答的供体
潜在的但低的GVHD风险仍然是HCT中未满足的主要需求。
多基因多态性KIR受体与其HLA配体结合,控制NK
功能,决定NK库内容并建立过程中NK细胞应答的阈值
被称为"NK教育"。HCT的大型回顾性研究表明,特异性KIR-HLA
与NK教育相关的等位基因组合可预测复发控制,但它们代表了
只有一小部分已知的KIR-HLA相互作用。此外,在数千种表现型中,
在NK细胞库中,负责HCT中白血病控制的NK细胞群是未知的,
移植对之间可能存在差异。Aim 1提出了一种机器学习方法来集成NK
基因型、表型和功能,以确定基因型如何决定总体库反应,
哪些亚群对全球反应的贡献最大。NK基因型的平行统计建模
在2800例AML患者的队列中,HCT结果可以证实相同的基因型,
整体反应也在HCT结果中发挥作用,但也可能发现意外结果。
HLA是GVHD风险最重要的决定因素。精确的HLA配型降低了
GVHD,但对于缺乏HLA相容性供体的患者,预测可允许的HLA错配是一个很好的方法。
最重要和未满足的需求。基于M和T前导肽,存在两种HLA-B同种异型谱系
HLA不匹配的HCT中的GVHD风险取决于前导基因的匹配状态而不同。
将HLA-B基因座分为两个谱系为定位功能基序提供了一种新的方法
在移植中,去除减少了先前
排除了一次检查超过1个残留物。使用HLA数据的机器学习方法
从11,000多名移植患者中提取的DNA将允许评估谱系变异的全谱
以及T细胞和NK同种异体反应之间的关系。
英文摘要
ABSTRACT
Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for most forms of acute
myelogenous leukemia (AML), but its 50% failure rate remains unacceptably high, with the principal
causes of death due to disease relapse and graft-versus-host disease. When successful, HCT prevents
leukemic relapse due to a graft versus leukemia effect, co-mediated by T cell and natural killer (NK) cell
immune functions. Selection of donors whose allografts will provide higher NK anti-leukemic response
potential but low GVHD risk remains a major unmet need in HCT.
The polygenic, polymorphic KIR receptors, in combination with their HLA ligands, control NK
function, dictating NK repertoire content and establishing thresholds for NK cell response in a process
called “NK education”. Large retrospective studies in HCT have demonstrated that specific KIR-HLA
allele combinations associated with NK education are predictive for relapse control, but they represent
only a fraction of known KIR-HLA interactions. Furthermore, out of the thousands of phenotypes present
in the NK repertoire, the NK population(s) responsible for leukemia control in HCT is unknown and they
likely differ between transplant pairs. Aim 1 proposes a machine learning approach to integrate NK
genotype, phenotype, and function to identify how genotype determines overall repertoire response and
which subpopulations contribute most to global response. Parallel statistical modeling of NK genotypes
and HCT outcome in a cohort of 2800 AML patient may confirm the same genotypes that are potent for
global response also play a role in HCT outcomes but may also identify unexpected ones.
HLA is the most important determinant of GVHD risk. Precise HLA matching lowers the risk for
GVHD, but for patients who lack HLA-compatible donors, predicting permissible HLA mismatches is a
paramount and unmet need. Two lineages of HLA-B allotypes exist based on the M and T leader peptide
dimorphism, and GVHD risk in HLA-mismatched HCT differs depending on the match status of the leader.
The division of the HLA-B locus into two lineages provides a novel approach for mapping functional motifs
in transplantation that removes reduces the sheer numbers of polymorphic positions that previously
precluded examination of more than 1 residue at a time. Machine learning approaches using HLA data
from more than 11,000 transplant patients will permit assessment of the full spectrum of lineage variation
and the relationship between T-cell and NK alloresponses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome
-
批准号:10390447
-
项目类别:
-
资助金额:$70.98万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome
-
批准号:10590647
-
项目类别:
-
资助金额:$73.31万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
-
批准号:10534187
-
项目类别:
-
资助金额:$59.59万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
Natural killer cell and T-cell crosstalk in CMV infection
-
批准号:9398188
-
项目类别:
-
资助金额:$30.63万
-
财政年份:2017
-
负责人:KATHARINE C HSU
-
依托单位:
KIR and HLA in cis and trans cooperatively shape human NK education
-
批准号:9160652
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2016
-
负责人:KATHARINE C HSU
-
依托单位:
KIR and HLA in cis and trans cooperatively shape human NK education
-
批准号:9310137
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2016
-
负责人:KATHARINE C HSU
-
依托单位:
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma
-
批准号:9488351
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2016
-
负责人:KATHARINE C HSU
-
依托单位:
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes
-
批准号:9271228
-
项目类别:
-
资助金额:$57.34万
-
财政年份:2015
-
负责人:KATHARINE C HSU
-
依托单位:
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes
-
批准号:8865414
-
项目类别:
-
资助金额:$42.1万
-
财政年份:2015
-
负责人:KATHARINE C HSU
-
依托单位:
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
-
批准号:8508896
-
项目类别:
-
资助金额:$34.4万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
-
批准号:8217684
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
-
批准号:8544192
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
-
批准号:8730476
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
-
批准号:8731836
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
-
批准号:8373670
-
项目类别:
-
资助金额:$36.44万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:7743072
-
项目类别:
-
资助金额:$42.08万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:8197289
-
项目类别:
-
资助金额:$41.65万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:7383207
-
项目类别:
-
资助金额:$42.13万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:7536389
-
项目类别:
-
资助金额:$42.08万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Receptors and Bone Marrow Transplant Outcome
-
批准号:6704624
-
项目类别:
-
资助金额:$12.91万
-
财政年份:2004
-
负责人:KATHARINE C HSU
-
依托单位:
海外基金